BRIEF—OeAW and Boeh-Ing Foundation establish new Institute for biomedical AI in Vienna

18 September 2024

The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS).

The new institute, called AITHYRA, will make revolutionary advances in biomedicine by developing AI-based research approaches. It will make a significant contribution to the advancement of human health with the knowledge gained from working with AI.

The foundation and OeAW were able to win Michael Bronstein, DeepMind Professor at the University of Oxford, as founding director of the institute. Two thirds of the funds required for the housing of the institute will be provided by the Federal Ministry of Education, Science and Research and one third by a grant from the City of Vienna.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical